HomeCompareCRUBW vs ABBV

CRUBW vs ABBV: Dividend Comparison 2026

CRUBW yields 250000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRUBW wins by $4.567699004441311e+30M in total portfolio value
10 years
CRUBW
CRUBW
● Live price
250000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.567699004441311e+30M
Annual income
$4,564,107,688,187,857,300,000,000,000,000,000,000.00
Full CRUBW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CRUBW vs ABBV

📍 CRUBW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRUBWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRUBW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRUBW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRUBW
Annual income on $10K today (after 15% tax)
$21,250,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,879,491,534,959,678,500,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CRUBW beats the other by $3,879,491,534,959,678,500,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRUBW + ABBV for your $10,000?

CRUBW: 50%ABBV: 50%
100% ABBV50/50100% CRUBW
Portfolio after 10yr
$2.2838495022206556e+30M
Annual income
$2,282,053,844,093,928,700,000,000,000,000,000,000.00/yr
Blended yield
99.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CRUBW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRUBW buys
0
ABBV buys
0
No recent congressional trades found for CRUBW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRUBWABBV
Forward yield250000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.567699004441311e+30M$102.3K
Annual income after 10y$4,564,107,688,187,857,300,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.567463897060879e+30M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CRUBW vs ABBV ($10,000, DRIP)

YearCRUBW PortfolioCRUBW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$25,010,700$25,000,000.00$11,550$430.00+$25.00MCRUBW
2$58,462,976,402$58,436,214,953.27$13,472$627.96+$58462.96MCRUBW
3$127,722,124,784,416$127,659,569,399,665.92$15,906$926.08+$127722124.77MCRUBW
4$260,784,910,907,288,130$260,648,248,233,768,800.00$19,071$1,382.55+$260784910907.27MCRUBW
5$497,657,939,618,196,950,000$497,378,899,763,526,240,000.00$23,302$2,095.81+$497657939618196.94MCRUBW
6$887,590,576,640,622,200,000,000$887,058,082,645,230,600,000,000.00$29,150$3,237.93+$887590576640622208.00MCRUBW
7$1,479,547,418,610,237,200,000,000,000$1,478,597,696,693,231,600,000,000,000.00$37,536$5,121.41+$1.4795474186102372e+21MCRUBW
8$2,305,052,548,351,757,200,000,000,000,000$2,303,469,432,613,844,500,000,000,000,000.00$50,079$8,338.38+$2.3050525483517572e+24MCRUBW
9$3,356,370,330,330,650,300,000,000,000,000,000$3,353,903,924,103,914,000,000,000,000,000,000.00$69,753$14,065.80+$3.3563703303306504e+27MCRUBW
10$4,567,699,004,441,311,000,000,000,000,000,000,000$4,564,107,688,187,857,300,000,000,000,000,000,000.00$102,337$24,771.77+$4.567699004441311e+30MCRUBW

CRUBW vs ABBV: Complete Analysis 2026

CRUBWStock

Crucible Acquisition Corporation does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on the software technology sectors, including business-to-business or business-to-consumer applications, infrastructure software, vertical software, marketplaces, payments, and ecommerce. The company was incorporated in 2020 and is based in Boulder, Colorado.

Full CRUBW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CRUBW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRUBW vs SCHDCRUBW vs JEPICRUBW vs OCRUBW vs KOCRUBW vs MAINCRUBW vs JNJCRUBW vs MRKCRUBW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.